Genocea to Present at Two March Investor Conferences

CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. GNCA, a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at two upcoming investor conferences:

• Cowen and Company 38^th Annual Health Care Conference
  Monday, March 12, 2018 at 11:20 AM ET in Boston, Massachusetts

• Needham & Co. Annual Healthcare Conference
  Tuesday, March 27, 2018 at 10:30 AM ET in New York, New York

A live webcast of both presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcasts will be archived for 30 days following the conference.

About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. For more information, please visit www.genocea.com.

For media:
Jennifer LaVin
O: 617-715-6687
jennifer.lavin@genocea.com

For investors:
Jonathan Poole
O: 617-876-8191
jonathan.poole@genocea.com